Medical researcher, Professor Grant Ramm, from QIMR Berghofer Medical Research Institute will be working with The University of Queensland’s UniQuest, Murdoch University and Vancouver-based PreveCeutical Medical Inc. (PMI) on a gene therapy project to treat diabetes and obesity.
Obesity and Diabetes are considered among the greatest challenges confronting both the Australian health care system and those internationally.
Professor Grant Ramm, who is currently the head of the Hepatic Fibrosis Group and Coordinator of the Cell and Molecular Biology Department at QIMR Berghofer Medical Research Institute said the project will aim to find new and more effective treatments for those struggling with diabetes and obesity.
“Existing treatments for diabetes and obesity have proven to be sub-optimal either lacking efficacy or prone to side-effects, and none have a demonstrated impact on the underlying cause,” Professor Ramm said.
“This new project will forge an outstanding collaboration to tackle these epidemics, bringing skills in nanomedicine, pharmacology, nucleic acid drug therapies, gene targeting and delivery systems, liver pathobiology and cell & molecular biology.”
Professor Ramm will be collaborating with researchers Dr. Harendra (Harry) Parekh from The University of Queensland’s School of Pharmacy and Dr. Rakesh Veedu from Murdoch University.
The research program will commence in September 2017 and will be conducted over four-years.